Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmuPharma updates on cancer compound Phase I/IIa clinical trial
ImmuPharma’s clinical trial began last summer and up to now two lower dose levels have been tested. The initial dose level of 1 mg/kg did not show any
ImmuPharma’s clinical trial began last summer and up to now two lower dose levels have been tested. The initial dose level of 1 mg/kg did not show any
The study is designed to provide additional data, if required, by the US Food and Drug Administration (FDA) for the approval of RHUCIN at the 50 U/kg dose.
The study results showed that TMC435 was safe and well-tolerated with no clinically relevant differences in adverse events between treatment groups and standard of care. In the treatment
FT1050 is a small, SCM-designed molecule which enhances hematopoietic stem cell support during the normal course of a stem cell transplant in patients suffering from hematologic malignancies, such
Datong’s products will equip Elsevier to foray into the emerging clinical decision support (CDS) market in China, thereby helping Chinese hospitals to improve their quality of care through
Acadra is an investigational, intravenous, small molecule that is transformed to its monophosphate active form (ZMP) once present within cells. It selectively induces apoptosis to B-cell leukemic cells
Reportedly, Wockhardt was the first in Asia and only the fourth company in the world to have developed, manufactured and marketed Wosulin, recombinant insulin injectables. As a result
The first global, phase 3, double-blind, randomized study, known as TMC435-C208 or QUEST-1 (QD dosing of TMC435 of previously untreated Genotype 1 patienTs-1), will evaluate a single TMC435
Through the proposal, BARDA seeks to procure 1.7 million courses of a smallpox antiviral. The proposal states that the contract would contain an option to obtain up to
With this patents grant Novexatin, currently in phase 2b-ready clinical trial stage, moves closer to further clinical development and commercialisation. NovaBiotics’ granted and pending IP not only protects